Zero-shot Learning of Drug Response Prediction for Preclinical Drug Screening

• URL: http://arxiv.org/abs/2310.12996v1
• Date: Thu, 5 Oct 2023 05:55:41 GMT
• Title: Zero-shot Learning of Drug Response Prediction for Preclinical Drug Screening
• Authors: Kun Li, Yong Luo, Xiantao Cai, Wenbin Hu, Bo Du
• Abstract summary: We propose a zero-shot learning solution for the. task in preclinical drug screening. Specifically, we propose a Multi-branch Multi-Source Domain Adaptation Test Enhancement Plug-in, called MSDA.
• Score: 38.94493676651818
• License: http://arxiv.org/licenses/nonexclusive-distrib/1.0/
• Abstract: Conventional deep learning methods typically employ supervised learning for drug response prediction (DRP). This entails dependence on labeled response data from drugs for model training. However, practical applications in the preclinical drug screening phase demand that DRP models predict responses for novel compounds, often with unknown drug responses. This presents a challenge, rendering supervised deep learning methods unsuitable for such scenarios. In this paper, we propose a zero-shot learning solution for the DRP task in preclinical drug screening. Specifically, we propose a Multi-branch Multi-Source Domain Adaptation Test Enhancement Plug-in, called MSDA. MSDA can be seamlessly integrated with conventional DRP methods, learning invariant features from the prior response data of similar drugs to enhance real-time predictions of unlabeled compounds. We conducted experiments using the GDSCv2 and CellMiner datasets. The results demonstrate that MSDA efficiently predicts drug responses for novel compounds, leading to a general performance improvement of 5-10\% in the preclinical drug screening phase. The significance of this solution resides in its potential to accelerate the drug discovery process, improve drug candidate assessment, and facilitate the success of drug discovery.

Related papers

• Regressor-free Molecule Generation to Support Drug Response Prediction [83.25894107956735]
  Conditional generation based on the target IC50 score can obtain a more effective sampling space. Regressor-free guidance combines a diffusion model's score estimation with a regression controller model's gradient based on number labels.
  arXiv  Detail & Related papers  (2024-05-23T13:22:17Z)
• Enhancing Acute Kidney Injury Prediction through Integration of Drug Features in Intensive Care Units [0.0]
  The relationship between acute kidney injury (AKI) prediction and nephrotoxic drugs has yet to be explored in the critical care setting. This study proposes a novel approach that leverages patient prescription data as a modality to improve existing models for AKI prediction.
  arXiv  Detail & Related papers  (2024-01-09T05:42:32Z)
• ADRNet: A Generalized Collaborative Filtering Framework Combining Clinical and Non-Clinical Data for Adverse Drug Reaction Prediction [49.56476929112382]
  Adverse drug reaction (ADR) prediction plays a crucial role in both health care and drug discovery. We propose ADRNet, a generalized collaborative filtering framework combining clinical and non-clinical data for drug-ADR prediction.
  arXiv  Detail & Related papers  (2023-08-03T11:28:12Z)
• HyGNN: Drug-Drug Interaction Prediction via Hypergraph Neural Network [0.0]
  Drug-Drug Interactions (DDIs) may hamper the functionalities of drugs, and in the worst scenario, they may lead to adverse drug reactions (ADRs) This paper proposes a novel Hypergraph Neural Network (HyGNN) model based on only the SMILES string of drugs, available for any drug, for the DDI prediction problem. Our proposed HyGNN model effectively predicts DDIs and impressively outperforms the baselines with a maximum ROC-AUC and PR-AUC of 97.9% and 98.1%, respectively.
  arXiv  Detail & Related papers  (2022-06-25T22:48:27Z)
• SSM-DTA: Breaking the Barriers of Data Scarcity in Drug-Target Affinity Prediction [127.43571146741984]
  Drug-Target Affinity (DTA) is of vital importance in early-stage drug discovery. wet experiments remain the most reliable method, but they are time-consuming and resource-intensive. Existing methods have primarily focused on developing techniques based on the available DTA data, without adequately addressing the data scarcity issue. We present the SSM-DTA framework, which incorporates three simple yet highly effective strategies.
  arXiv  Detail & Related papers  (2022-06-20T14:53:25Z)
• Multi-View Substructure Learning for Drug-Drug Interaction Prediction [69.34322811160912]
  We propose a novel multi- view drug substructure network for DDI prediction (MSN-DDI) MSN-DDI learns chemical substructures from both the representations of the single drug (intra-view) and the drug pair (inter-view) simultaneously and utilizes the substructures to update the drug representation iteratively. Comprehensive evaluations demonstrate that MSN-DDI has almost solved DDI prediction for existing drugs by achieving a relatively improved accuracy of 19.32% and an over 99% accuracy under the transductive setting.
  arXiv  Detail & Related papers  (2022-03-28T05:44:29Z)
• Deep learning for drug repurposing: methods, databases, and applications [54.08583498324774]
  Repurposing existing drugs for new therapies is an attractive solution that accelerates drug development at reduced experimental costs. In this review, we introduce guidelines on how to utilize deep learning methodologies and tools for drug repurposing.
  arXiv  Detail & Related papers  (2022-02-08T09:42:08Z)
• When deep learning meets causal inference: a computational framework for drug repurposing from real-world data [12.68717103979673]
  Existing methods for drug repurposing may exist translational issues when applied to human beings. We present an efficient and easily-customized framework for generating and testing multiple candidates for drug repurposing. We demonstrate our framework in a case study of coronary artery disease (CAD) by evaluating the effect of 55 repurposing drug candidates on various disease outcomes.
  arXiv  Detail & Related papers  (2020-07-16T21:30:56Z)

This list is automatically generated from the titles and abstracts of the papers in this site.

This site does not guarantee the quality of this site (including all information) and is not responsible for any consequences.